U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Lung Non-Squamous Non-Small Cell Carcinoma

MedGen UID:
1660179
•Concept ID:
C4324656
•
Neoplastic Process
Synonym: Non-Squamous Non-Small Cell Lung Carcinoma

Definition

A non-small cell lung carcinoma without evidence of squamous differentiation. [from NCI]

Professional guidelines

PubMed

Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up.
Finall A, Davies G, Jones T, Emlyn G, Huey P, Mullard A
J Clin Pathol 2023 Jun;76(6):391-399. Epub 2022 Jan 18 doi: 10.1136/jclinpath-2021-207987. PMID: 35042754

Recent clinical studies

Etiology

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J
Lancet Oncol 2022 Feb;23(2):220-233. Epub 2022 Jan 14 doi: 10.1016/S1470-2045(21)00650-1. PMID: 35038432
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW
Lancet Respir Med 2021 May;9(5):467-475. Epub 2020 Oct 20 doi: 10.1016/S2213-2600(20)30391-X. PMID: 33096027
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F
Lancet Oncol 2019 Jul;20(7):924-937. Epub 2019 May 20 doi: 10.1016/S1470-2045(19)30167-6. PMID: 31122901
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group
Lancet 2017 Jan 21;389(10066):255-265. Epub 2016 Dec 13 doi: 10.1016/S0140-6736(16)32517-X. PMID: 27979383Free PMC Article
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators
Lancet Oncol 2016 Nov;17(11):1497-1508. Epub 2016 Oct 10 doi: 10.1016/S1470-2045(16)30498-3. PMID: 27745820Free PMC Article

Diagnosis

Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications.
Kazdal D, Hofman V, Christopoulos P, Ilié M, Stenzinger A, Hofman P
Genes Chromosomes Cancer 2022 May;61(5):244-260. Epub 2022 Jan 22 doi: 10.1002/gcc.23022. PMID: 34997651
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J, Boland A, Bates V, Vecchio F, Dundar Y, Chaplin M, Green JA
Cochrane Database Syst Rev 2021 Mar 18;3(3):CD010383. doi: 10.1002/14651858.CD010383.pub3. PMID: 33734432Free PMC Article
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW
Lancet Respir Med 2021 May;9(5):467-475. Epub 2020 Oct 20 doi: 10.1016/S2213-2600(20)30391-X. PMID: 33096027
Targeting HER2 expression in cancer: New drugs and new indications.
Vranić S, Bešlija S, Gatalica Z
Bosn J Basic Med Sci 2021 Feb 1;21(1):1-4. doi: 10.17305/bjbms.2020.4908. PMID: 32530388Free PMC Article
ALK inhibitors and advanced non-small cell lung cancer (review).
Rossi A, Maione P, Sacco PC, Sgambato A, Casaluce F, Ferrara ML, Palazzolo G, Ciardiello F, Gridelli C
Int J Oncol 2014 Aug;45(2):499-508. Epub 2014 May 29 doi: 10.3892/ijo.2014.2475. PMID: 24889366

Therapy

Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, Poran A, Sheen JH, Kohler V, Esaulova E, Srouji J, Ramesh S, Vyasamneni R, Karki B, Sciuto TE, Sethi H, Dong JZ, Moles MA, Manson K, Rooney MS, Khondker ZS, DeMario M, Gaynor RB, Srinivasan L
Cancer Cell 2022 Sep 12;40(9):1010-1026.e11. Epub 2022 Aug 25 doi: 10.1016/j.ccell.2022.08.003. PMID: 36027916
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Li S, McGuire K, Kaul M, Paccaly A, Quek RGW, Gao B, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Gullo G, Rietschel P
Nat Med 2022 Nov;28(11):2374-2380. Epub 2022 Aug 25 doi: 10.1038/s41591-022-01977-y. PMID: 36008722Free PMC Article
Targeting HER2 expression in cancer: New drugs and new indications.
Vranić S, Bešlija S, Gatalica Z
Bosn J Basic Med Sci 2021 Feb 1;21(1):1-4. doi: 10.17305/bjbms.2020.4908. PMID: 32530388Free PMC Article
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F
Lancet Oncol 2019 Jul;20(7):924-937. Epub 2019 May 20 doi: 10.1016/S1470-2045(19)30167-6. PMID: 31122901
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group
Lancet 2017 Jan 21;389(10066):255-265. Epub 2016 Dec 13 doi: 10.1016/S0140-6736(16)32517-X. PMID: 27979383Free PMC Article

Prognosis

Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
Pérol M, Felip E, Dafni U, Polito L, Pal N, Tsourti Z, Ton TGN, Merritt D, Morris S, Stahel R, Peters S
Ann Oncol 2022 May;33(5):511-521. Epub 2022 Feb 23 doi: 10.1016/j.annonc.2022.02.008. PMID: 35218887
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.
West HJ, McCleland M, Cappuzzo F, Reck M, Mok TS, Jotte RM, Nishio M, Kim E, Morris S, Zou W, Shames D, Das Thakur M, Shankar G, Socinski MA
J Immunother Cancer 2022 Feb;10(2) doi: 10.1136/jitc-2021-003027. PMID: 35190375Free PMC Article
Targeting HER2 expression in cancer: New drugs and new indications.
Vranić S, Bešlija S, Gatalica Z
Bosn J Basic Med Sci 2021 Feb 1;21(1):1-4. doi: 10.17305/bjbms.2020.4908. PMID: 32530388Free PMC Article
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F
Ann Oncol 2020 Nov;31(11):1491-1505. Epub 2020 Aug 24 doi: 10.1016/j.annonc.2020.07.014. PMID: 32853681
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M
Lancet 2014 Aug 23;384(9944):665-73. Epub 2014 Jun 2 doi: 10.1016/S0140-6736(14)60845-X. PMID: 24933332

Clinical prediction guides

Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, Poran A, Sheen JH, Kohler V, Esaulova E, Srouji J, Ramesh S, Vyasamneni R, Karki B, Sciuto TE, Sethi H, Dong JZ, Moles MA, Manson K, Rooney MS, Khondker ZS, DeMario M, Gaynor RB, Srinivasan L
Cancer Cell 2022 Sep 12;40(9):1010-1026.e11. Epub 2022 Aug 25 doi: 10.1016/j.ccell.2022.08.003. PMID: 36027916
Targeting HER2 expression in cancer: New drugs and new indications.
Vranić S, Bešlija S, Gatalica Z
Bosn J Basic Med Sci 2021 Feb 1;21(1):1-4. doi: 10.17305/bjbms.2020.4908. PMID: 32530388Free PMC Article
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F
Ann Oncol 2020 Nov;31(11):1491-1505. Epub 2020 Aug 24 doi: 10.1016/j.annonc.2020.07.014. PMID: 32853681
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators
Lancet 2019 May 4;393(10183):1819-1830. Epub 2019 Apr 4 doi: 10.1016/S0140-6736(18)32409-7. PMID: 30955977
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group
Lancet Respir Med 2019 May;7(5):387-401. Epub 2019 Mar 25 doi: 10.1016/S2213-2600(19)30084-0. PMID: 30922878

Recent systematic reviews

Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
O'Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G, Eccles LJ, Varol N, Waser N, Penrod JR, Goring S
Lung Cancer 2023 Mar;177:11-20. Epub 2023 Jan 11 doi: 10.1016/j.lungcan.2023.01.006. PMID: 36669321
A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
Shao T, Zhao M, Liang L, Tang W
Front Immunol 2022;13:948597. Epub 2022 Oct 26 doi: 10.3389/fimmu.2022.948597. PMID: 36389713Free PMC Article
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
Siciliano MA, Caridà G, Ciliberto D, d'Apolito M, Pelaia C, Caracciolo D, Riillo C, Correale P, Galvano A, Russo A, Barbieri V, Tassone P, Tagliaferri P
ESMO Open 2022 Jun;7(3):100465. Epub 2022 Apr 12 doi: 10.1016/j.esmoop.2022.100465. PMID: 35427835Free PMC Article
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J, Boland A, Bates V, Vecchio F, Dundar Y, Chaplin M, Green JA
Cochrane Database Syst Rev 2021 Mar 18;3(3):CD010383. doi: 10.1002/14651858.CD010383.pub3. PMID: 33734432Free PMC Article
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U, Tsourti Z, Vervita K, Peters S
Lung Cancer 2019 Aug;134:127-140. Epub 2019 May 30 doi: 10.1016/j.lungcan.2019.05.029. PMID: 31319971

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...